tiprankstipranks
I-Mab Announces CMO Transition, Interim Successor Named
Company Announcements

I-Mab Announces CMO Transition, Interim Successor Named

I-Mab Adr (IMAB) has released an update.

I-Mab has announced the resignation of their Chief Medical Officer Dr. John Hayslip, who is departing to pursue new opportunities and whose exit is not due to internal conflicts. In the interim, the company has engaged Dr. Louie Naumovski, a seasoned professional with over 30 years in the biopharmaceutical industry, specializing in oncology drug development. The search for a permanent successor is currently underway.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskI-Mab Announces Major Leadership Overhaul
TheFlyI-Mab announces leadership transitions
TipRanks Auto-Generated NewsdeskI-Mab Biopharma: Innovating Cancer Treatments
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!